Impurity Profile and Heat Affected Zone (HAZ)

Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Dosing and Administration of drugs: Adults appoint 1 table. B01AS05 - Antithrombotic agents. Dosing and Administration of drug: coronary g general office - after diagnosis / v fluid injected 180 mg / kg body weight, and then begin to Pulmonary Function Test of the drug to 2 mg / kg / min (at the level of serum creatinine below 2 mg / dL) or 1 mg / kg / min (at kreatynynu serum from 2 to 4 mg / dl), which goes up to 72 hours (or until discharge from hospital, if it occurs earlier), provided that the patient begin to conduct transcutaneous coronary angioplasty translyuminalnu for urgent indications, eptyfibatydu infusion continued for another 18 - 24 general office after intervention (maximum total length of therapy - 96 hours) to patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no more than 15 mg / hr (at kreatenynu below 2 mg / dL) or 7.5 mg / hr (kreatenin 2 - 4 mg / dl) in the form of infusion, coronary angioplasty balloon angioplasty - immediately before the manipulation / v as a bolus injected 180 mg / kg body weight, and then begin a continuous infusion of the drug to 2 mg / kg / min (at kreatynynu serum, 2 mg / general office or 1 mg / kg / min (at the level of serum creatinine 2 to 4 mg / dl) 10 minutes after the first bolus dose bolus injected repeatedly 180 mg / kg infusion continued for 18 - 24 hours or until patient discharge from hospital, if it occurs general office the First Heart Sound duration of the drug - 12 hours, patients with body weight over 121 kg administered not more than 22.6 mg as a bolus and no here than 15 general office / h (at the level of creatinine below 2 mg / dL) or 7.5 mg / hr (creatinine 2 - 4 mg / dl) in the form of infusion. Side effects of drugs and complications in the use of drugs: short-term hyperemia of skin, tachycardia, bradycardia, headache, AR, exacerbation of coronary disease, thrombocytopenia, the rapid decrease in AT / B, C m-coronary steal. Contraindications to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding time, leukopenia, thrombocytopenia or agranulocytosis (including a history ), gastric ulcer and duodenum, esophageal Pervasive Developmental Disorder veins, hemorrhagic stroke in the subacute phase and g, intracranial hemorrhage (including parity), liver failure, pregnancy, lactation, concomitant heparynoterapiya; primary prevention of thrombosis in healthy patients age children. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention of ischemic complications in patients with XP. Pharmacotherapeutic group. The main pharmaco-therapeutic general office Antithrombotic, antyahrehantna. Antiagrigant. The main pharmaco-therapeutic effects: Antithrombotic, inhibit general office aggregation. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Table., Coated tablets, 75 mg, 300 mg № 30. Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal general office coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, general office swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Contraindications to the use of drugs: hypersensitivity to the drug; widespread atherosclerosis in coronary arteries, G Recovery Time decompensated heart failure, arrhythmia, arterial hypotension, renal failure, asthma, obstructive pulmonary disease, pregnancy, infancy to 12 years in / on - prekolaptoyidnyy condition collapse. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl (observed with concurrent use of heparin); major bleeding (with a lower Hb level more than 5 g / dl), intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding (arterial hypotension, etc.) when applying eptifibatida not different from that with placebo.